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Abstract 
Human T cell leukemia virus type‑1 (HTLV‑1) was the first retrovirus found to cause cancer in humans, but the mecha‑
nisms that drive the development of leukemia and other diseases associated with HTLV‑1 infection remain to be 
fully understood. This review describes the functional properties of p13, an 87‑amino acid protein coded by HTLV‑1 
open reading frame II (orf‑II). p13 is mainly localized in the inner membrane of the mitochondria, where it induces 
potassium  (K+) influx and reactive oxygen species (ROS) production, which can trigger either proliferation or apop‑
tosis, depending on the ROS setpoint of the cell. Recent evidence indicates that p13 may influence the cell’s innate 
immune response to viral infection and the infected cell phenotype. Association of the HTLV‑1 transcriptional activa‑
tor, Tax, with p13 increases p13’s stability, leads to its partial co‑localization with Tax in nuclear speckles, and reduces 
the ability of Tax to interact with the transcription cofactor CBP/p300. Comparison of p13 sequences isolated from 
HTLV‑1‑infected individuals revealed a small number of amino acid variations in the domains controlling the subcel‑
lular localization of the protein. Disruptive mutations of p13 were found in samples obtained from asymptomatic 
patients with low proviral load. p13 sequences of HTLV‑1 subtype C isolates from indigenous Australian patients 
showed a high degree of identity among each other, with all samples containing a pattern of 5 amino acids that 
distinguished them from other subtypes. Further characterization of p13’s functional properties and sequence vari‑
ants may lead to a deeper understanding of the impact of p13 as a contributor to the clinical manifestations of HTLV‑1 
infection.
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Background
Human T cell leukemia virus type 1 (HTLV-1) is a retro-
virus that causes an aggressive neoplasm of mature  CD4+ 
T cells called adult T cell leukemia (ATL), as well as a 
variety of inflammatory diseases including uveitis, infec-
tious dermatitis, Sjögren’s syndrome, and HTLV-1-asso-
ciated myelopathy/tropical spastic paraparesis (HAM/
TSP) [1–8]. Although at least 5–10 million people are 
infected with HTLV-1 worldwide, only a small percentage 
will develop clinically relevant symptoms [9]. The factors 
that determine the clinical outcome of HTLV-1 infection 
are not fully understood, but studies aimed at investigat-
ing the viral determinant of HTLV-1 pathogenicity have 
underscored the oncogenic potential of Tax and HBZ 
[10].
Despite having a relatively small genome of approxi-
mately 9000 nt [11], HTLV-1 expresses multiple gene 
products through the transcription of both strands of its 
proviral genome, complex mRNA splicing, and ribosomal 
frameshifting, resulting in the production of protease and 
polymerase enzymes, the structural Gag and Env pro-
teins, and the non-structural proteins Tax, Rex, p21Rex, 
p30, p13, p12/p8, and HBZ. This review describes the 
biological properties of p13, a small protein encoded by 
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the second open reading frame of the X region (orf-II) 
[12]. As we explore here, recent studies have revealed 
interesting variations in p13 sequences isolated from dif-
ferent patients infected with HTLV-1 [13, 14] that may 
possibly be relevant to the life cycle and pathogenic prop-
erties of HTLV-1.
Expression and intracellular localization of p13
Early studies of orf-II revealed that it codes for two pro-
teins: p30, a 241-residue nuclear/nucleolar protein 
expressed from a doubly-spliced mRNA, and p13, an 
87-residue protein coded by a singly-spliced mRNA cor-
responding to the carboxy-terminal portion of p30 [12, 
15, 16]. Analyses of the expression kinetics of the viral 
transcripts in infected cells showed that the p13 and p30 
mRNAs accumulate late in the replication cycle, together 
with mRNAs encoding structural proteins [17, 18]. Initial 
studies carried out in a HeLa-derived cell line transiently 
transfected with p13 expression plasmids indicated that 
the protein accumulated in punctate structures located 
in the cytosol and perinuclear area, and in the nucleus 
but not nucleoli [15]. Subsequent co-localization analy-
sis with compartment markers revealed that the punc-
tate structures containing p13 were in fact mitochondria 
[19]. The results of mutational analyses and assays with 
GFP-tagged portions of p13 led to the identification 
of the minimal mitochondrial targeting signal (MTS) 
that is necessary and sufficient to determine the pro-
tein’s mitochondrial accumulation (Fig.  1) [19]. Circular 
dichroism analysis showed that the p13 MTS folds into 
an amphipathic alpha helical structure containing four 
arginines [20]. Unlike canonical MTS, the p13 MTS dif-
fers is not located at the amino terminus of the protein, 
it is not cleaved upon import, and it does not require the 
presence of the four arginines for mitochondrial locali-
zation [20]. The mitochondrial localization of p13 was 
confirmed by confocal microscopy analysis and a combi-
nation of electron microscopy and biochemical fractiona-
tion studies, which revealed that p13 is mainly inserted 
in the inner mitochondrial membrane [20]. Confocal 
microscopy analysis also confirmed mitochondrial locali-
zation in transfected primary rat embryo fibroblasts and 
the T cell acute lymphoblastic leukemia (T-ALL) cell line 
Jurkat [21].
The MTS of p13 acts as a dominant targeting signal 
that is necessary for the mitochondrial accumulation of 
p13, and is sufficient to direct the mitochondrial accu-
mulation of heterologous proteins such as GFP [19]. The 
13-kDa size of p13 is well below the cut-off of the nuclear 
pore, suggesting that the protein should be able to freely 
diffuse in and out of the nucleus. As depicted in Fig.  1, 
p13 is believed to contain a nuclear localization signal 
(NLS) positioned after its MTS. The existence of this NLS 
was inferred from observations from a series of deletion 
mutants of p30 fused to GFP [22], and further analysis is 
required to verify its impact on p13’s intracellular com-
partmentalization. A study by Andresen et  al. showed 
that p13 becomes more stable when co-expressed with 
Tax, that it is modified by ubiquitination, and that a small 
fraction of p13 is localized to nuclear speckles contain-
ing Tax and SC35 (Fig. 2) [23]. Interestingly, the nuclear 
localization of p13 was more prominent when the pro-
tein was fused to green fluorescent protein (GFP) or to 
the hemagglutinin (HA) epitope tag (unpublished data). 
The nuclear accumulation of p13-GFP also appeared to 
be proportional to the expression levels of the protein 
(Fig. 2). These findings suggest that p13 may accumulate 
in the nucleus when a certain concentration threshold is 
reached, which might be favored by Tax or the presence 
of tags such as ubiquitin.
Functional properties of p13
Effects of p13 on  K+ flux
Studies carried out using synthetic p13 and purified 
mitochondria showed that the protein induces a potas-
sium influx through the inner mitochondrial membrane 
(Δψ) [20, 24]. The entry of  K+ increases the activity of the 
electron transport chain (ETC), which extrudes a higher 
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Fig. 1 p13 domain structure. Schematic representation of the domain structure of p13. AA indicates the amphipathic α‑helix overlapping with 
the mitochondrial targeting signal (MTS, amino acids 21–35) and +++ indicates the four arginines present in the MTS. The transmembrane region 
(TM) includes amino acids 30–40. A region with a high flexibility score (H) spans amino acids 42–48. A predicted β‑sheet structure spans amino 
acids 65–75. The proline‑rich C‑terminus contains two overlapping P‑x‑x‑P motifs implicated in interactions with SH3 domain‑containing proteins. A 
putative cryptic nuclear localization sequence (NLS) is mapped to a region spanning residues 43–80. This figure was adapted from Figure 1 in [87]
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number of  H+ and thus balances the entry of  K+ positive 
charges. Although this ramping up of the ETC maintains 
the potential of the mitochondrial membrane, it also 
favors the production of reactive oxygen species (ROS). 
Increased ROS may trigger the opening of the mitochon-
drial permeability transition pore (PTP), an event that 
can lead to cell death [25] (Fig. 3).
Cells expressing p13 have fragmented mitochondria 
[20]. The effect of p13 in both isolated mitochondria and 
in cells is dose-dependent: When p13 is low, the entry 
of  K+ is counterbalanced by increased ETC activity. At 
higher levels of p13, cells show mitochondrial depolari-
zation and substantial fragmentation. Although the four 
arginines in the amphipathic alpha helix are not essential 
for mitochondrial targeting, they are required to induce 
the inflow of  K+ into mitochondria and for mitochon-
drial fragmentation [20, 24].
p13 and mitochondrial ROS
ROS are powerful second messengers that control mul-
tiple signal transduction pathways. Depending on their 
levels, ROS may favor cell proliferation, neoplastic trans-
formation, or cell death. The effects of ROS in cell turno-
ver have been compared to a rheostat [26]: a moderate 
increase in ROS stimulates healthy resting cells to prolif-
erate, and a further increase will favor tumor transforma-
tion. Excessive ROS production will lead to DNA damage 
and apoptotic cell death.
In agreement with observations made in isolated mito-
chondria, p13 was found to increase ROS production in 
several cell models (e.g. HeLa cells, primary T cells, and 
Jurkat T-ALL cells) [25]. These findings suggest that, in 
the context of the viral life cycle, p13 might contribute 
to an expansion of the pool of infected T cells, but trig-
ger apoptosis of infected cells that acquire a transformed 
phenotype. In line with this model, the expression of p13 
has been shown to lead to the activation of primary T 
cells and increased apoptotic death of Jurkat T-ALL cells 
[25].
Role of p13 in calcium signaling
p13 also influences the mitochondrial uptake of calcium 
ions. In response to physiological stimuli (nutrients, hor-
mones, neurotransmitters),  Ca2+ rapidly accumulates in 
the mitochondrial matrix, where it stimulates enzymes of 
oxidative metabolism to produce ATP [27]. In contrast, 
mitochondrial calcium overload triggers sustained PTP 
opening, which leads to cell death [28].
Experiments carried out using  Ca2+-sensitive aequorin 
probes localized to different cellular compartments 
(mitochondria, ER, or cytosol) showed that p13 inhibits 
the influx of  Ca2+ into mitochondria, resulting in a local 
increase in the cytosolic concentration of  Ca2+ (Fig.  3) 
[29]. This effect is interesting in light of the crucial role 
of  Ca2+ signaling in the activation and survival of T cells, 
the primary targets of HTLV-1 infection. It would be 
interesting to determine if p13 functionally interacts with 
p12, a small, hydrophobic orf-I protein that localizes in 
the ER, binds calreticulin, and increases cytosolic  Ca2+ 
levels, resulting in the activation of nuclear factor of acti-
vated T cells (NFAT) [15, 30].
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Fig. 2 Intracellular localization of p13‑GFP. a Confocal microscopy 
analysis of HeLa cells transfected with a p13‑GFP‑expressing plasmid 
and labelled with an antibody recognizing the mitochondrial protein 
HSP60 (Santa Cruz Biotechnology) and an Alexa‑546‑conjugated 
secondary antibody (Life Technologies). Nuclei were visualized using 
Vibrant DyeCycle Ruby (Life Technologies). Nuclei, mitochondria, and 
p13 are shown in blue, red, and green, respectively. b Quantitative 
analysis of the percentage of p13‑GFP signal detected in nucleus in 
relation to the total p13‑GFP signal measured in the same cell
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Effects of p13 on cell signaling pathways
Lefebvre et  al. showed that p13 negatively influ-
ences the Ras signal transduction pathway by bind-
ing to farnesyl pyrophosphate synthase (FPase), a key 
enzyme in the synthesis of substrates necessary for the 
prenylation of Ras and its association with the plasma 
membrane (Fig.  2) [31]. This property may contribute 
to the ability of p13 to suppress the transformation of 
rat embryo fibroblasts driven by the combination of 
Ras and Myc [32]. p13 also inhibits the proliferation 
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Fig. 3 Overview of p13 biology. (1) p13 accumulates in the inner mitochondrial membrane. It induces an inward  K+ current which leads to 
decreased mitochondrial membrane potential (Δψ) and a compensatory increase in the activity of the ETC, resulting in increased ROS production, 
and opening of the PTP, leading to mitochondrial swelling and apoptosis. p13 also interferes with the uptake of  Ca2+ by mitochondria, which leads 
to an accumulation of cytosolic calcium. (2) When p13 is co‑expressed with Tax, p13 becomes ubiquitinated and more stable. The protein partially 
accumulates in the nucleus, where p13 and Tax co‑localize in nuclear speckles. (3) Interaction of p13 with farnesyl pyrophosphate synthase (FPase) 
interferes with Ras prenylation and targeting to the plasma membrane
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of Jurkat cells when grown at high culture density and 
favors cell death under glucose deprivation or upon 
treatment with C2-ceramide, an inducer of the intrinsic 
pathway of apoptosis [33].
The C-terminal portion of p13 (and p30) is rich 
in prolines, including those arranged in a sequence 
resembling P-x-x-P (PPII) helical motifs that interact 
with SH3 domain-containing proteins such as the Src 
family kinases (SFKs). Using in vitro binding and kinase 
assays, Tibaldi et al. confirmed that p13 is able to asso-
ciate with SFKs Src, Fyn, Fgr, and Lyn [34]. This inter-
action led to increased kinase activity, but the effect 
was blocked in the presence of a p13 peptide spanning 
residues 61–87. Further analysis of the p13-Lyn inter-
action provided evidence that p13 is able to direct Lyn 
to mitochondria, resulting in an accumulation of p13-
Lyn complexes in the intermembrane space instead of 
the inner membrane location observed for p13 alone. 
This change in p13’s submitochondrial localization was 
accompanied by an attenuation in the p13-mediated 
loss of mitochondrial membrane potential [34]. These 
p13-SFK interactions share some similarities with 
properties described for HIV-1 Nef, whose interactions 
with the Hck, Lyn, and Src SFKs play a positive role in 
viral replication [35, 36].
The role of autophagy in recycling damaged or 
unneeded organelles has gained increased attention in 
recent years. Mitophagy is a mitochondria-specific sub-
type of this recycling mechanism that can be induced 
by different factors, including viral infection [37]. 
Mitophagy induced by Hepatitis viruses B and C has 
been suggested to reduce apoptosis and increase viral 
persistence [38, 39]. Coxsackie B virus (CVB) uses the 
mitophagy process for its viral spread [40], and classical 
swine fever virus (CSFV) induces mitophagy to inhibit 
apoptosis [41]. The effects of p13 on mitochondrial 
depolarization, swelling, and general homeostasis might 
therefore trigger the mitophagy process. The role of p13 
in regulating essential parts of the mitophagy pathway 
would be an interesting point of investigation for future 
studies.
Impact of p13 on Tax function
Studies on the interplay between p13 and Tax [23] indi-
cated that p13 binds directly to Tax and interferes with 
its ability to associate with CBP/p300, an interaction that 
is needed for Tax-mediated activation of transcription 
from the long terminal repeat (LTR) promoter. Together 
with its late expression kinetics, this property supports 
a role for p13 as an ‘off’ switch that favors entrance into 
a latent state of infection, which is likely important for 
virus persistence in the host [23].
p13‑like proteins in other deltaretroviruses
HTLV-1 is classified in the deltaretrovirus genus, 
together with the related HTLV-2, 3, and 4 orthologues 
that infect nonhuman primates as simian T cell leuke-
mia virus (STLVs); and bovine leukemia virus (BLV). 
Due to their shared molecular features, the human and 
simian viruses are collectively referred to as primate 
T-lymphotropic viruses (PTLVs).
HTLV-2 circulates as 2 major subtypes, A and B, and 
is present mainly in South American indigenous popu-
lations, western and central Africa, and among intrave-
nous drug users [42]. The pathogenicity of HTLV-2 is 
not clearly defined [43], but infection with this virus 
appears to significantly increase all-cause mortality 
[44]. The HTLV-2 x-II orf codes for a protein named 
p28 that, despite limited sequence identity, shares 
several functional properties with HTLV-1 p30 [45]. 
Transfection assays carried out using a plasmid coding 
for an HTLV-2A x-II orf carrying an epitope tag at the 
3ʹ end did not reveal expression of any proteins smaller 
than p28, suggesting that HTLV-2A does not code for a 
p13 homologue [46]. Analogous experiments have not 
been carried out for HTLV-2B.
HTLV-3 [47, 48] and HTLV-4 [49] were identi-
fied in individuals from Cameroonian rainforests 
and are of unknown pathogenicity [50]. As part of a 
detailed analysis of the coding potential of HTLV-4 
isolate 1863LE, Switzer et  al. identified an open read-
ing frame (orf-IV) that codes for a 68-amino acid pro-
tein with 75% similarity to portions of p13 located after 
the MTS and transmembrane motif [49]. Interestingly, 
alignment of this predicted protein with p13, HTLV-2 
p28, and related orfs in STLV-2 (orf-II) and HTLV-3 
(orf-III) revealed a highly conserved stretch of amino 
acids corresponding to p13 residues 59–84 in all of the 
sequences [49]. Afonso et  al. [51] recently described a 
divergent STLV-1 isolate that contains mutations that 
affect splicing and/or codons that disrupt both the 
x-II and x-I orfs. An extension of this analysis to other 
STLVs and HTLVs showed disruption of either or both 
of these orfs in several other PTLVs [51].
BLV is a widespread pathogen that infects cattle, water 
buffalo, and zebus, and causes B-lymphocytosis, leuke-
mia, and lymphoma. Accessory proteins coded by BLV 
include G4, a 105-amino acid protein that is targeted 
to mitochondria, and to a lesser extent, to the nucleus 
[31]. p13 and G4 share very little sequence identity 
(26.4%, unpublished data), and its mitochondrial target-
ing depends on both an amino-proximal hydrophobic 
alpha-helix and a more carboxy-terminal arginine-rich 
amphipathic alpha helix [31]. In contrast to the tumor 
suppressor-like property observed for p13, BLV G4 
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cooperates with H-Ras in a rat embryo fibroblast trans-
formation model, and is needed for BLV-driven tumor 
development in a sheep model [52].
p13 and the host immune response
Several studies over the past decade have revealed impor-
tant roles for mitochondria in immune responses [53]. 
Many viruses encode mitochondrial proteins that are 
important for viral spread and persistence [54–56], and 
several viruses target MAVS (mitochondrial antiviral-
signaling protein), a cellular protein localized in the outer 
mitochondrial membrane, mitochondrial-associated 
membranes, and peroxisomes that plays a critical role in 
innate immune response against RNA viruses [57–59]. 
The ability of HTLV-1 to infect monocytes suggests that 
the virus might impinge on the host’s innate immune 
responses [60–63].
One way that p13 might impact the host’s immune 
response could be through its regulation of cell death. 
Cell death mechanisms induced through mitochondrial 
pathways are known to enable the release of circular 
mitochondrial DNA (mtDNA) from mitochondria to 
the cytosol [64]. The presence of mtDNA in the cytosol 
can further trigger inflammatory responses in the host 
through the cyclic GMP–AMP synthase (cGAS)-stim-
ulator of interferon genes (STING) signaling pathway 
[65, 66]. The possible impact of p13 on anti-viral innate 
immunity is currently under investigation in our labora-
tories. The size and shape of mitochondria are controlled 
by the balance between mitochondrial fusion and fis-
sion [67]. This dynamic is intimately connected to the 
pattern of differentiation and activation of cells involved 
in immune responses. Naive effector T cells have small, 
round mitochondria, and their activation to effector T 
cells increases mitochondrial fission [68]. Mitochon-
drial fusion is prevalent in memory T cells, and results 
in elongated, tubular mitochondria and higher mitochon-
drial mass [68]. In their initial description of alterna-
tively spliced HTLV-1 mRNAs, Berneman et al. showed 
that the p13 mRNA was expressed in 6 out of 10 ATLL 
samples, but was not detected in 3 PBMC samples from 
healthy HTLV-1 carriers [69]. It would be interesting to 
investigate if p13 might be involved in the selection of 
memory T-cells, which may represent the cell of origin of 
ATL [70].
In vivo studies of p13
In vivo studies performed in rabbits using the molecu-
lar clone ACH.1 or a derivative containing a muta-
tion that abolished expression of both orf-II proteins 
(ACH.30/13.1) showed that animals inoculated with 
ACH.30/13.1 had lower proviral loads than animals 
inoculated with ACH.1. These results suggest that p13 
and/or p30 might be essential for the maintenance of 
viral loads in  vivo [71]. The importance of p13 in  vivo 
was confirmed in a more recent study of a molecu-
lar clone lacking the p13 initiation codon but still able 
to produce p30 [72]. However, in both studies the p13 
knock-out was obtained by substituting its ATG start 
codon with GAT, which also disrupts the HBZ orf coded 
on the antisense strand [73]. New studies that do not 
interrupt the HBZ orf are thus needed to verify the 
importance of p13 alone.
Sequence variation of p13
While the HTLV-1 genome structure and sequence are in 
general highly conserved, sequence variations in HTLV-1 
LTR segments are used to classify HTLV-1 isolates into 7 
molecular subtypes with characteristic geographic distri-
butions: subtypes A (further divided into 5 subgroups), B, 
C, D, E, F, and G [9]. Several studies have been directed 
at identifying subtypes and variants that might correlate 
with the clinical characteristics of infected patients. A 
study by Nozuma et al. comparing isolates from asymp-
tomatic carriers and HAM/TSP patients confirmed the 
virus’s high degree of sequence conservation but also 
provided evidence for an association between HAM/
TSP and infection with the “transcontinental” HTLV-1A 
subgroup [14]. Interestingly, this subgroup also showed a 
significantly higher frequency of mutations, mainly sin-
gle nucleotide substitutions [14]. Kuramitsu investigated 
viral parameters associated with indeterminate HTLV-1 
western blot (WB) results, defined as a lack of antibody 
reactivity against gp46Env and/or Gag proteins p53, p24 
and p19, and observed that WB-indeterminate patients 
had a higher frequency of viral sequence variations com-
pared to patients with positive WB results [13]. Even 
more notable was the median proviral load, which was 
almost 100-fold lower in this group. Kuramitsu et al. sug-
gest that the low proviral load might be due to mutations 
in the provirus that reduce viral replication and limit dis-
semination within the host [13].
Using the datasets from these studies, we analyzed the 
p13 sequence in isolates from patients with different clini-
cal characteristics. As a reference sequence, we used the 
p13 sequence coded by viral isolate ATK (accession num-
ber J02029.1), which was derived from a Japanese ATL 
patient and is considered to be a prototype for subtype 
A viruses [11]. A search using the Basic Local Alignment 
Search Tool (BLAST; https ://blast .ncbi.nlm.nih.gov/Blast 
.cgi) yielded 69 hits obtained from published sequences 
[12–14, 74]. Although the majority (78%) of the sequences 
shared 100% identity with p13 coded by ATK (not shown), 
17 isolates showed amino acid variations (Fig.  4). Inter-
estingly, two of these sequences have stop codons result-
ing in the early termination of p13 (isolates K1015 and 
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AC0007, Fig. 4). K1015, an isolate from the WB-indeter-
minate group [13], has an early termination codon at posi-
tion 24 that results in the loss of all the domains essential 
for p13’s intracellular targeting and functional proper-
ties. This isolate also has stop codons in Pol and Env (not 
shown). Isolate AC0007, from an asymptomatic carrier 
[14], has a stop codon at position 54 and thus retains the 
MTS and transmembrane sequence, but lacks most of 
the putative nuclear localization sequence (NLS) of p13 
(Fig. 4). Two other isolates have a single amino acid dif-
ference in the MTS domain. None of the sequences in the 
BLAST search matched with p13 coded by the CS-clone 
of HTLV-1, which was derived from a North American 
ATL patient [75] and carries a single amino acid differ-
ence in the MTS and one in the putative NLS. All of the 
samples with variations in the MTS were from HAM/TSP 
or ATL patients who had positive WB results. None of the 
variations in the MTS involve the four arginines identified 
as critical for p13 function [20].
Amino acid variations within p13’s putative NLS were 
identified in six of the sequences: three in the WB-
indeterminate group, and three in the WB-positive 
group (Fig. 4) [13]. Two of the latter sequences carried 
an asparagine in place of serine at position 70 (S70N). 
Although Kuramitsu et  al. concluded that the sam-
ples from the group with indeterminate WB results 
had the highest frequency of sequence variations [13], 
the majority of isolates with p13 variations were from 
patients with either an HTLV-1 associated disease or 
detectable antigens in WB analysis. Further studies 
are needed to determine if the variations observed in 
the patients with positive WB results or disease actu-
ally influence the function of p13. It is notable that the 
two isolates coding for truncated p13 proteins were 
obtained from asymptomatic carriers who did not have 
positive WB results, suggesting a possible link between 
p13 and disease development.
J02029.1   ATK MLIISPLPRVWTESSFRIPSLRVWRLCTRRLVPHLWGTMFGPPTSSRPTGHLSRASDHLGPHRWTRYRLSSTVPYPSTPLLPHPENL
CS-HTLV-1  MLIISPLPRVWTESSFRIPSLRVWRLCARRLVPHLWGTMFGPPTSSRPTGHLSRASDHLGPHRWTRYQLSSTVPYPSTPLLPHPENL 
BAX34861.1 FHAM012 MLIISPLPRVWTEPSFRIPSLRVWRLCTRRLVPHLWGTMFGPPTSSRPTGHLSRASDHLGPHRWTRYRLSSTVPYPSTPLLPHPENL 
BAX76693.1 K1006WBind MLIISPLPRVWTESSFRIPSLRVWRLCTRRLVPHLWRTMFGPPTSSCPTGHLSRASDHLGPHRWTRYRLSSTVPYPSTPLLPHPENL 
BAX76717.1 K1019WBind MLIISPLPRVWTESSFRIPSLRVWRLCTRRLVPHLWGTMFGPPTSSRPTGHLSRTSDHLGPHRWTRYRLSSTVPYPSTPLLPHPKNL 
B YRTWRHPGLHDSARSLHGTPRSSTPPGFMTGWLHPVLRRTCLRWVRLSPIRFSSETWVRPLPSIILMdniBW8200S56767XA QLSSTVPYPSTPLLPHPENL 
B PLPSIILM7100K84967XA KVWTESSFRIPSLRVWRLCTRRLVPHLWGTMFGPPTSSRPTGHLSRASDHLGPHRWTRYRLSSTVPYPSTPLLPHPENL 
B LRYRTWRHPGLHDSARSLHGTPRSSTPPGFMTGWLHPVLRRTCLRWVRLSPIRFSSETWVRPLPSIILM0500K80177XA NSTVPYPSTPLLPHPENL 
BAX76884   K0A38 MLIISPLPRVWTESSFRIPSLRVWRLCTRRLVPHLWGTMFGPPTSSRPTGHLSRASDHLGPHRWTRYRLNSTVPYPSTPLLPHPENL 
B TGWLHPVLRRTCLRWVRLSPIRFSSETWVRPLPSIILM42A0K23177XA VFGPPTSSRPTGHLSRASDHLGPHRWTRYRLSSTVPYPSTPLLPHPENL 
B PGLHDSARSLHGTPRSSTPPGFMTGWLHPVLRRTCLRWVRLSPIRFSSETWVRPLPSIILM6000T29277XA YRWTRYRLSSTVPYPSTPLLPHPENL 
B PHPLLPTSPYPVTSSLRYRTWRHPGLHDSARSLHGTPRSSTPPGFMTGWLHPVLRRTCLRWVRLSPIRFSSETWVRPLPSIILM3300K02077XA KNL 
B RLSPIRFSSETWVRPLPSIILM9100T84377XA IWRLCTRRLVPHLWGTMFGPPTSSRPTGHLSRASDHLGPHRWTRYRLSSTVPYPSTPLLPHPENL 
B FMTGWLHPVLRRTCLRWVRLSPIRFSSETWVRPLPSIILM9400K00177XA SPPTSSRPTGHLSRASDHLGPHRWTRYRLSSTVPYPSTPLLPHPENL 
Q80794    MLIISPLPRVWTESSFRIPSLRVSRLCTRRLVPHLWGTMFGPPTSSRPTGHLSRASDHLGPHRWTRYRLSSTVPYPSTPLLPHPENL 
BBA30575   AAA45391  MLIISPLPRVWTEPSFQIPSLRVWRLCTRRLVPHLWGTMFGPPTSSRPTGHLSRASDHLGPHRWTRYRLSSTVPYPSTPLLPHPENL 
AAB23361.1  MLIISPLPRVWTESSFRIPSLRVWRLCTRRLVPHLWGTMFGPPTSSRPTGHLSRASDHLGPHRWTRYRLSSTVPYPSTPLLPHPEML 
B *SLHGTPRSSTPPGFMTGWLHPVLRRTCLRWVRLSPIRFSSETWVRPLPSIILM700CA66743XA
B ETWVRPLPSIILM5101K10767XA PSFRIPSLRV* 
Fig. 4 HTLV‑1A p13 sequence alignments. GenBank accession numbers and isolate names are indicated in the left column. Isolate CS‑HTLV [75] is 
not deposited in GenBank. Its p13 sequence was determined by Sanger sequencing in our laboratory. Sequence variations are highlighted in pink. 
The mitochondrial targeting signal (MTS) and the putative nuclear localization sequence (NLS) are highlighted in yellow and blue, respectively. The 
multi‑alignment was performed with the Mega7 program using default parameters
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Sequence variations in p13 coded by HTLV‑1 subtypes 
A and C
HTLV-1 C, present mainly in Australia and Melanesia, 
has recently gained attention due to it high prevalence 
(in up to 40% of adults) in indigenous populations liv-
ing in remote regions of central Australia [76]. Unlike 
subtype A, subtype C seems to be more frequently 
associated with inflammatory disease in the lungs, 
causing bronchiectasis or bronchitis with high mor-
bidity [77, 78]. However, cases of infectious dermati-
tis and ATL have also been reported for HTLV-1C [79, 
80]. The reasons for the different pathogenic proper-
ties of the two subtypes are still unclear.
Pairwise sequence comparisons at the nucleotide and 
amino acid levels between HTLV-1A and HTLV-1C 
show that the structural genes, gag, pol, pro, and env 
are more highly conserved compared to the pX region, 
suggesting that the X-region proteins might contrib-
ute to the different clinical manifestations observed in 
infected individuals [81]. To gain additional insight into 
the role of p13 in HTLV-1 pathogenesis, we extended 
our analysis to the p13 proteins coded by 37 subtype 
C sequences, 34 of which were isolated from Austral-
ian patients (Fig. 5) [82–85]. Sequence information for 
4 amino-terminal amino acids was not available for 8 
GenBank entries (prefix KC in Fig. 5). Since these amino 
acids were invariant in the other sequences, we chose to 
compare amino acids 5–87 for the full set of sequences. 
The analysis revealed 89–95% identity between ATK 
and the 37 HTLV-1C sequences, 90–100% identity 
among all HTLV-1C sequences, and 98–100% identity 
among the 34 Australian sequences, with 31 out of 34 
showing 100% identity. Interestingly, all 34 Australian 
sequences share an 8-amino acid ‘signature’ that dis-
tinguishes them from ATK. The first three residues of 
this signature are present in the entire set of HTLV-1C 
sequences (Fig. 5).
Overall, this analysis confirms similar amino acid 
sequences and conservation of the principal domains 
described for HTLV-1A p13, including the MTS, the 
transmembrane region, the putative NLS region and the 
P-x-x-P SH3 binding motif. It is notable that the MTS 
is perfectly matched among all of the sequences. Inter-
estingly, three of the ‘Australian signature’ residues are 
located in the putative NLS region, and the last signature 
residue is a carboxy-terminal proline, which would add a 
third potential P-x-x-P motif.
Whether these changes affect the function of p13 
and contribute to the distinct pathogenic properties 
of the HTLV-1C clade found in indigenous Austral-
ian patients [83] should be a point of investigation in 
future studies.
Conclusions
Many studies have shed light on the expression, intracel-
lular trafficking, and function of p13, but the function of 
this protein in the context of the complete viral genome 
remains elusive. Given the importance of mitochondria 
in anti-viral innate immunity, it will also be important to 
discover if, by targeting mitochondria, p13 may hamper 
the host cell’s anti-viral responses. Notably, several other 
human tumor viruses also code for mitochondrial pro-
teins, with diverse effects on mitochondrial function and 
the viral life cycle [56].
In vivo study of a molecular clone of HTLV-1 without 
changing the start codon of HBZ is essential for deter-
mining the true importance of p13 in HTLV-1 infection. 
Galli et al. showed the possibility of utilizing humanized 
mice for studying the p12 protein of HTLV-1 in the whole 
virus using infected primary  CD4+ cells [86]. This model 
may be useful for better assessing the pathogenic poten-
tial of p13 and investigating the intracellular localiza-
tion of the protein in different tissues in infected animals 
in vivo. The identification of new roles for mitochondria 
opens up new questions about the role of p13 in both 
the pathogenesis of HTLV-1 and in immune responses. 
HTLV-1C involves up to half of some communities in 
endemic foci in Australia. The remarkable concentration 
of this virus demands that the functional role of p13 be 
better understood, and presents an opportunity to inves-
tigate the effects of the different sequence variations in 
the functional domains of p13.
(See figure on next page.)
Fig. 5 Alignments of p13 coded by HTLV‑1A prototype ATK and 37 HTLV‑1C isolates. GenBank accession numbers and/or isolate names are 
indicated in the left column. Patient isolates 9–31 are described in [82]. Isolates from Australia are indicated in bold. Isolates NCP201, VAN‑EM5, and 
MEL5 were obtained from New Caledonia, Vanuatu [84], and the Solomon Islands [85], respectively. Sequence variations are highlighted in pink. The 
mitochondrial targeting signal (MTS) and the putative nuclear localization sequence (NLS) are highlighted in yellow and blue, respectively. Arrows 
at the bottom of the figure indicate an 8‑residue ‘signature’ present in all Australian isolates (see text). The multi‑alignment was performed with the 
Mega7 program using default parameters
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J02029.1   ATK MLIISPLPRVWTESSFRIPSLRVWRLCTRRLVPHLWGTMFGPPTSSRPTGHLSRASDHLGPHRWTRYRLSSTVPYPSTPLLPHPENL
JX891479 AUS-NR  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
KF242505   AUS-DF  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
KF242506   AUS-CS MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
JX891478   AUS-GM MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
KC786941   AUS-GN ---?SPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
KC786942   AUS-NA ---?SPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
KC786943   AUS-SQ ---?SPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
KC786944   AUS-MI ---?SPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
KC786947   AUS-AN ---?SPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
KC786949   AUS-DM ---?SPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
KC786952   AUS-RI ---?SPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
KC786958   AUS-LT ---?SPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
KX905203   NCP201 MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMFGPLTSSRPTGHLSGASDHLGPHRWTRYRLSSTIPYPSAPLLPHPENL 
K TWVRPLPSIILM5ME-NAV1.202509X KSSLRISSLRVWRLCTRRLVPHLWGTMFGPPTSSRPTGHLSGASDHLGPHRWTRYRLSSTIPYPSAPLLPHPENL 
L02534     MEL5  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMFGPPTSSRPTGHLSRASDHLGPHRWTRYRLSSTVPYPSAPLLPHPENL 
patient 9  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 10  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 11  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 12  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 13  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 14  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHR?TRYRLS?TIPYPSTPLLPHPENP
patient 15  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 16  MLIISP?PRVGTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 17  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 18  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 19  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 20  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 21  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 22  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 23  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPSTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 24  MLIISPLPRVWTKSSLRIS?LRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 25  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 26  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 27  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 29  MLIISPLPRVWTKSSLRISRLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 30  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
patient 31  MLIISPLPRVWTKSSLRISSLRVWRLCTRRLVPHLWGTMLGPPTSSRPTGHLPRTSDHLGPHRWTRYRLSSTIPYPSTPLLPHPENP
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